Home » Salud » Page 2
Tag:

Salud

Health

Dr. Tree: Gel Íntimo Calmante e Hidratante para la Salud Íntima Femenina

by Dr. Priya Deshmukh - Senior Editor, Health
written by Dr. Priya Deshmukh - Senior Editor, Health

Maintaining optimal intimate hygiene is crucial for overall well-being, yet it’s a topic often shrouded in silence. Increasingly, open conversations are normalizing the importance of proper care for this delicate area. Selecting the appropriate products requires careful consideration, as the intimate zone possesses a unique pH and specific needs demanding tailored formulas and professional backing.

The growing awareness of these needs has led to the development of specialized products, such as those offered by Dr. Tree, a dermocosmetic brand from Phergal Laboratorios, focused on natural and sustainable skincare. Their range for intimate care includes a cleansing gel for daily hygiene and a hydrating cream designed to provide relief and moisture. Choosing the right products can significantly improve comfort and prevent common issues like dryness, itching, and irritation.

Formulated with a focus on respecting the skin’s natural microbiome, these products aim to restore balance and provide soothing relief. According to Cristina Carrillo, a pharmacist and collaborator with Dr. Tree, “It’s not enough to simply maintain cleanliness; it’s essential to preserve the pH balance and vaginal microbiota to prevent discomfort such as dryness, itching, burning, or recurrent infections.”

Understanding the Ingredients for Intimate Wellness

Dr. Tree’s calming, hydrating, and refreshing gel-cream boasts a formula with 96.3% ingredients of natural origin. Key components include strawberry extract, known for its hydrating, calming, and regenerative properties; hyaluronic acid, which enhances hydration and elasticity; and ectoin, creating a cellular shield against external aggressors. The formula also incorporates Centella Asiatica extract, recognized for its regenerative capabilities, inositol to support a healthy skin barrier, nourishing chia seed oil, and calming blue daisy extract. It features an adaptive pH (5 ± 0.2) combined with the TRIBIOTIC complex.

Clinical testing demonstrated that 100% of consumers reported immediate comfort, hydration, and softness after using the gel-cream, with an average rating of 9.4 out of 10 among regular users of leading brands. The gel-cream is designed for external application, with one to two pumps applied to clean, dry skin.

A Gentle Cleansing Option for the Whole Family

Dr. Tree’s intimate gel is formulated to protect and support the balance of the vaginal flora, making it suitable for the entire family, including young children. It works by stimulating natural defenses, neutralizing odor, and alleviating itching. Carrillo emphasizes the importance of a pH-balanced cleanser, stating, “As a pharmacist, I particularly value complete options for daily intimate hygiene. Dr. Tree’s intimate gel with a physiological pH of 5.5 is ideal for this area. It’s gentle, hypoallergenic, and respects even the most sensitive skin. Beyond cleansing, it soothes and helps strengthen the skin microbiome, which is fundamental for preventing irritation and maintaining natural balance.”

This gel, certified by ECOCERT and containing 99.7% ingredients of natural origin, includes blue daisy extract for its calming and antioxidant effects, chia seed oil to restore the skin barrier, alpha glucan oligosaccharide to protect the microbiome, and a natural hydration complex with a lasting effect of up to 72 hours. To use, apply to moistened skin, massage to create a lather, and rinse thoroughly with water.

Studies approved by dermatologists and gynecologists showed 100% user satisfaction. According to data from IQVIA, Dr. Tree’s dermoprotective intimate gel ranked 10th among the best-selling products in the intimate hygiene market within the pharmacy channel, both online and offline, during 2024. IQVIA is a leading provider of data and analytics in the healthcare industry.

Frequently Asked Questions

Both the gel and cream are hypoallergenic and formulated for sensitive skin. The recommended order of application is to use the intimate gel for cleansing followed by the hydrating cream. The hydrating cream comes in a 50 ml container, while the intimate gel is available in 200 and 400 ml sizes.

Choosing the right intimate care products is a personal decision, but understanding the importance of pH balance, natural ingredients, and dermatological testing can support individuals make informed choices for their well-being.

As research continues to illuminate the complexities of the vaginal microbiome and its impact on overall health, staying informed about available options and consulting with healthcare professionals remains paramount. The increasing availability of gentle, pH-balanced products like those offered by Dr. Tree represents a positive step towards normalizing intimate care and empowering individuals to prioritize their health.

Please share your thoughts and experiences in the comments below. We encourage you to share this article with anyone who might locate it helpful.

Disclaimer: This article provides informational content and should not be considered medical advice. Always consult with a qualified healthcare professional for personalized guidance on intimate health concerns.

0 comments
0 FacebookTwitterPinterestEmail
Health

Argentina: Early Flu Vaccine Campaign Due to New H3N2 Variant

by Dr. Priya Deshmukh - Senior Editor, Health
written by Dr. Priya Deshmukh - Senior Editor, Health

Argentina is preparing to launch its annual influenza vaccination campaign on March 9th, earlier than usual, in response to the detection of a new variant of the influenza A virus – H3N2, subclade K – and an anticipated increase in circulating respiratory viruses. The proactive measure aims to protect vulnerable populations before the peak of flu season, according to officials at the Ministry of Health.

Health officials emphasize the importance of early vaccination to mitigate potential strain on the public health system. While the H3N2, subclade K variant doesn’t appear to cause more severe illness, its increased contagiousness raises concerns about a surge in cases. The Ministry of Health has secured 8.16 million doses of influenza vaccine to ensure nationwide availability, with the first delivery of 795,760 doses – including both adjuvanted and adult formulations – already underway this week.

“We are anticipating the usual calendar to protect the population before the peak of viral circulation. Each year, respiratory viruses begin to circulate earlier. That’s why we decided to act early to avoid the possible impact of the new variants and care for those who need it most,” stated Minister of Health Mario Lugones. He also highlighted the logistical effort involved in accelerating the campaign, made possible by efficient resource management.

Who is Eligible for the Flu Vaccine?

The vaccination campaign prioritizes several key groups, including children aged 6 to 24 months, adults over 65, healthcare personnel, pregnant and postpartum women, and individuals with underlying health conditions. Specifically, 4.7 million doses are allocated for adults aged 2 to 64 with risk factors, 2.3 million doses for individuals over 65 (using the adjuvanted vaccine), and 1.16 million doses for children between six and 24 months.

Roberto Debbag, an infectologist and Vice President of the Latin American Society of Vaccinology (MN 60253), explained that the typical flu presentation begins with a persistent cough and nasal congestion, followed within 24 to 48 hours by classic flu symptoms like high fever, malaise, and lung discomfort. He stressed the importance of early attention to these signs, particularly in high-risk groups, as they can be easily confused with other respiratory infections, such as COVID-19. “Early consultation for high fever, intense fatigue, and breathing difficulties helps avoid complications and allows for a timely diagnosis,” Debbag noted.

Past Vaccination Coverage and Concerns

Coverage rates for the flu vaccine in recent years have been suboptimal. Data indicates that vaccination among adults over 65 ranged between 41.6% and 42.2% in the last three campaigns, while less than 70% of children under two years completed the two-dose schedule. Insufficient vaccination coverage could lead to increased hospital occupancy and the need for more intensive care, potentially disrupting other healthcare services.

Underlying health conditions that increase the risk of severe influenza include chronic respiratory or cardiac diseases, immunodeficiencies, oncohematological pathologies, a history of transplantation, diabetes, morbid obesity, and chronic kidney failure.

Campaign Logistics and Vaccine Safety

The vaccination campaign will be free of charge, and each province and the City of Buenos Aires will publish information regarding vaccination sites and schedules. The national government is centralizing logistics and distribution, while local jurisdictions will manage administration and communication. Minister Lugones affirmed that all vaccines on the National Calendar are safe and supported by scientific evidence, having been developed, tested, and approved to international standards.

Authorities warn that inadequate coverage could strain hospital capacity, increase referrals, and necessitate the rescheduling of non-urgent procedures, negatively impacting the healthcare system. They urge prioritized groups to receive the vaccine during the designated period.

Each provincial administration will implement communication and organizational strategies tailored to its needs, in coordination with the Ministry of Health, to ensure that the target population has adequate access to the advanced vaccination campaign. This preventative strategy aims to strengthen the national health system’s response to seasonal influenza and protect the most vulnerable sectors of the population through timely and effective immunization.

Disclaimer: This article provides informational content about public health and is not a substitute for professional medical advice. Always consult with a qualified healthcare provider for diagnosis and treatment of any medical condition.

What are your thoughts on the early rollout of the flu vaccine? Share your comments below, and please share this article with your network to facilitate spread awareness.

0 comments
0 FacebookTwitterPinterestEmail
Health

Itchy Skin: Scientists Discover Key to Stopping the Scratching Cycle

by Dr. Priya Deshmukh - Senior Editor, Health
written by Dr. Priya Deshmukh - Senior Editor, Health

The relentless urge to scratch is a common response to skin irritations, but resisting that impulse is crucial to prevent further damage. Now, scientists at the Université Catholique de Louvain in Brussels have pinpointed a key player in the body’s ability to notify us when to stop scratching: the ion channel TRPV4. This discovery, presented at the 70th Annual Meeting of the Biophysical Society in San Francisco, could revolutionize the treatment of chronic itch, a condition affecting millions worldwide.

Chronic itch presents a significant health challenge for individuals with conditions like eczema, psoriasis, or kidney disorders. While seasonal changes like cold and dry winter air can cause temporary irritation, many people experience persistent and debilitating itch. Understanding how the need to scratch arises and is regulated is essential, as the inability to control this impulse can worsen skin lesions and complicate underlying health issues. Researchers have long sought to understand the biological mechanisms that signal when scratching should cease, particularly as the problem disproportionately affects patients in Latin America and Spain, according to reporting from Audacy.

TRPV4: A Key Regulator of the Itch-Scratch Cycle

Researchers at the Université Catholique de Louvain have clarified how the TRPV4 ion channel functions in sensory neurons and its role in generating the internal signal to stop scratching. This protein belongs to a family of channels that act as molecular gates in cell membranes, allowing ions to flow in response to physical or chemical stimuli. Historically, TRPV4 has been studied in relation to pain, but its direct involvement in the sensation of itch was previously unproven. Roberta Gualdani, who led the research, explained that “instead of a phenotype related to pain, what emerged very clearly was a disruption in how scratching behavior is regulated,” as reported by Science News.

The study found that TRPV4 not only initiates the sensation of itch but also activates a negative feedback mechanism through sensory neurons. This signal is critical: it informs the spinal cord and brain that scratching has been sufficient, triggering the expected feeling of relief. Without this signal, the scratching behavior persists for longer than normal, potentially maintaining and even worsening discomfort in those suffering from chronic itch. This mechanism is particularly relevant for individuals with dermatological conditions, according to analysis from Audacy.

Mouse Model Reveals TRPV4’s Role

To pinpoint TRPV4’s function in controlling scratching, Gualdani’s team used a genetic mouse model. They selectively eliminated the channel in the sensory neurons of mice, allowing them to study its role without interfering with other tissues. The scientists induced a condition similar to atopic dermatitis in the engineered mice. The results were striking: mice lacking TRPV4 in their sensory neurons didn’t scratch as frequently, but when they did, the act of scratching lasted significantly longer than in control mice.

Gualdani described this phenomenon as paradoxical. “Without TRPV4, the mice don’t feel that feedback, so they continue scratching much longer than normal,” she explained to Audacy. This observation underscores the importance of TRPV4 in the negative feedback signal and suggests that its malfunction can increase the persistence of chronic itch.

Implications for Future Therapies

This discovery opens new avenues for developing targeted therapies against chronic itch, particularly in conditions like atopic dermatitis. The research highlights the need for treatments that act with greater precision. Blocking TRPV4 throughout the body doesn’t appear to be the optimal solution. Future strategies could focus on localized intervention on the skin, preserving essential nervous system function that inhibits the urge to scratch.

This knowledge regarding TRPV4’s role represents a step forward in the search for solutions for those suffering from persistent itch. Researchers recognize that future therapies will need to balance “the precision of the intervention with the protection of the neuronal mechanisms that tell us when we should stop,” a perspective that offers hope following this discovery, according to Audacy.

Disclaimer: This article provides informational content and should not be considered medical advice. Please consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.

What are your thoughts on this new research? Share your comments below, and help spread awareness by sharing this article with your network.

0 comments
0 FacebookTwitterPinterestEmail
Health

Rare Diseases in Mexico: Diagnosis, Treatment & Challenges (2024)

by Dr. Priya Deshmukh - Senior Editor, Health
written by Dr. Priya Deshmukh - Senior Editor, Health

Mexico is grappling with significant hurdles in the diagnosis and treatment of rare diseases, leaving an estimated 10 million citizens without timely access to specialized care and facing prolonged diagnostic odysseys. This gap underscores critical deficiencies in early detection, specialized attention, and dedicated research within the country’s healthcare system, according to data from the National Autonomous University of Mexico (UNAM).

Rare diseases, defined as those affecting fewer than one in 2,000 people, present a unique public health challenge. While individually uncommon, collectively they impact a substantial portion of the population. Globally, around 7,000 rare diseases have been identified, affecting an estimated 3% of the world’s population – more than 300 million individuals. The complexities are further compounded by the fact that approximately 80% of these conditions are chronic, debilitating, and have a genetic origin, often manifesting early in life.

The path to diagnosis for individuals with rare diseases in Mexico is often arduous. Patients frequently spend an average of five years navigating multiple specialists and undergoing extensive genetic testing and consultations at specialized centers before receiving a definitive diagnosis. This delay can significantly impact treatment outcomes and quality of life. Dr. Estefanía Torres, a leader in the Therapeutic Area at Takeda Mexico, a biopharmaceutical company providing treatments, emphasized that increasing awareness of these conditions is crucial to reducing diagnostic delays and preventing patients from years of uncertainty.

“The rarity lies in the disease, but the people and families affected are more common than one might think,” Dr. Torres stated.

The Long Road to Diagnosis

The lack of timely diagnosis remains a major obstacle in Mexico. The five-year average time to diagnosis highlights the demand for improved awareness among healthcare professionals and increased access to specialized diagnostic tools. Currently, Mexico has 25 public hospitals across 16 states accredited to treat rare diseases. Key referral centers for pediatric cases include the National Institute of Pediatrics and the Hospital Infantil de México ‘Federico Gómez,’ while other National Institutes of Health provide care for adults.

The UNAM plays a vital role in diagnostic efforts through its Unidad de Diagnóstico de Enfermedades Raras (UDER), the first National Specialized Center focused on the evaluation and personalized diagnosis of rare conditions. UDER can be reached at +52 55 5442-1727, Monday through Friday from 9:00 AM to 4:00 PM, or via email at [email protected]. The center is located at Fundación “Conde de Valenciana” (4º piso), calle Chimalpopoca # 14, Col Obrera, Cuauhtémoc, Ciudad de México. More information about UDER can be found on their website.

The World Health Organization (WHO) recognizes rare diseases as a global health priority, urging countries to strengthen diagnostic capabilities, treatment options, and comprehensive care. February 29th (or February 28th in non-leap years) is observed as World Rare Disease Day, dedicated to raising awareness about the challenges faced by those living with these conditions.

Global Recognition and Limited Treatments

Despite growing global awareness, effective treatments remain elusive for the vast majority of rare diseases. Less than 5% of these conditions currently have a specific treatment available, according to recent data. This underscores the urgent need for increased investment in research and development to address the unmet medical needs of this patient population.

REMEXER, a resource focused on rare diseases in Mexico, highlights the estimated 10 million Mexicans living with these conditions, but acknowledges the lack of precise data. You can find more information about REMEXER here.

As Mexico continues to address the challenges surrounding rare diseases, a collaborative approach involving healthcare providers, researchers, patient advocacy groups, and policymakers will be essential to improve outcomes and ensure equitable access to care. The focus will likely remain on improving diagnostic pathways, expanding access to specialized centers, and fostering research into novel therapies.

Disclaimer: This article provides informational content about rare diseases in Mexico and should not be considered medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment of any medical condition.

What are your thoughts on the challenges facing rare disease patients in Mexico? Share your comments below, and please share this article to raise awareness.

0 comments
0 FacebookTwitterPinterestEmail
Newer Posts
Older Posts
@2025 - All Right Reserved.

Hosted by ByoHosting - Most Recommendeed Webhhosting. For complains, abuse, advertising contact:
[email protected]

Adblock Detected

Please support us by disabling your AdBlocker extension from your browsers for our website.